A new prognostic model could potentially predict and stratify the risk for hepatocellular carcinoma (HCC) among patients with chronic hepatitis B (CHB) who are noncirrhotic and not indicated for ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced recent progress in the ongoing clinical development of its ...
The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...
The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...
Collaboration with South Korean university advocates early antiviral treatment for hepatitis B | Feb. 5, 2025 13:09 ...
Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
A new study published in the journal of Nature Scientific Reports found that anemia was almost three times as common in women ...
Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effectiveness of ...
New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback